Total
0
Shares
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon
Managing Director, Fleta Solomon
Source: AUManufacturing
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Little Green Pharma (LGP) has opened its share purchase plan (SPP) with aims to raise up to $5 million
  • Under the plan, eligible shareholders will be able to subscribe for up to $30,000 worth of shares, which are priced at 65 cents
  • This price represents a 17.3 per cent discount to the five-day volume-weighted average price
  • LGP will use the money to speed-up sales and marketing efforts in both Australia and overseas as well as expand its manufacturing capacity
  • Shares in Little Green Pharma have dropped 8.75 per cent and are trading at 73 cents each

Little Green Pharma (LGP) has opened its share purchase plan (SPP) with aims to raise up to $5 million.

This follows on from a recently announced placement to sophisticated, experienced and professional investors to raise $22 million.

All up, around 34 million shares were issued to participants at 65 cents.

Under the SPP, eligible shareholders will be able to subscribe for up to $30,000 worth of shares, which are also priced at 65 cents.

This price represents a 17.3 per cent discount to the five-day volume-weighted average price.

The company’s Australian-based Directors, Angus Caithness and Neale Fong, intend to apply for the maximum $30,000 worth.

In the event of oversubscriptions, LGP has the right to scale-back applications.

LGP will use the money from both the placement and share purchase plan to speed-up sales and marketing efforts in both Australian and overseas markets, and expand its manufacturing and cultivation capacity.

The plan is set to close on March 3 and shares will be issued on March 11 and begin trading on the ASX on March 12.

Shares in Little Green Pharma have dropped 8.75 per cent and are trading at 73 cents each at 1:56 pm AEDT.

LGP by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.